Common drugs, vitamins, nutritional supplements and COVID-19 mortality
Dr Steven Lehrer, Peter H Rheinstein
doi:10.3892/ijfn.2021.14
The FDA has approved only one drug, remdesivir, for the treatment of COVID-19. The FDA has granted an emergency use authorization for the rheumatoid arthritis treatment drug, baricitinib (Olumiant), for the treatment of COVID-19 in some cases. For this reason, investigators have paid considerable attention to the association between commonly used drugs and the outcome of patients with COVID-19. Aspirin and ibuprofen have been reported to reduce the mortality rate. Omeprazole can increase mortality. In addition, some studies have demonstrated that famotidine diminishes mortality, while others have indicated that famotidine leads to a poorer prognosis. The present study used UK Biobank (UKB) data to assess the association of commonly used drugs with COVID-19 mortality. Data processing was performed on Minerva, a Linux mainframe with Centos 7.6. The UK Biobank Data Parser (ukbb_parser) was used, a python-based package that allows easy interfacing with the large UK Biobank dataset. The results revealed that aspirin and omeprazole were associated with an elevated mortality rate. Ibuprofen-related mortality was lower than laxative-related mortality. Aspirin users were also significantly older than other subjects. The association with mortality of cholesterol-lowering medications, blood pressure-lowering medications, hormone replacement and oral contraceptives in 134 female subjects revealed insignificant variability. The association of nutritional supplements in 238 subjects with mortality indicated that variability was insignificant. The lower mortality linked to the supplementation of vitamin D and vitamin B, presumably B complex, has been previously observed. On the whole, the present study demonstrates that although some of the associations described among drugs and This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.
Ethics approval and consent to participate All patient data were from the UK Biobank. The UK Biobank application for the present study was approved as UKB project 57245, SL and PHR. Patient consent for publication Not applicable.
Competing interests The authors declare that they have no competing interests.
Author Manuscript The research reported in the present study was supported by the Office of Research Infrastructure of the National Institutes of Health under award nos. S10OD018522 and S10OD026880. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Manuscript
References
Aly, Ma, Should aspirin be used for prophylaxis of COVID-19-induced coagulopathy?, Med Hypotheses
Atkins, Masoli, Delgado, Pilling, Kuo et al., Preexisting comorbidities predicting COVID-19 and mortality in the UK Biobank community cohort, J Gerontol A Biol Sci Med Sci
Cangiano, Fatti, Danesi, Gazzano, Croci et al., Mortality in an Italian nursing home during COVID-19 pandemic: Correlation with gender, age, ADL, vitamin D supplementation, and limitations of the diagnostic tests, Aging
Chow, Khanna, Kethireddy, Yamane, Levine et al., Aspirin use is associated with decreased mechanical ventilation, ICU admission, and in-hospital mortality in hospitalized patients with COVID-19, Anesth Analg,
doi:10.1213/ANE.0000000000005292Flora, Maestra, Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19, FASEB J
Haque, Jawed, Akhter, Dar, Khan et al., Acetylsalicylic acid (Aspirin): A potent medicine for preventing COVID-19 deaths caused by thrombosis and pulmonary embolism, Eur Rev Med Pharmacol Sci
Kelleni, Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes, Biomed Pharmacother
Khanji, Aung, Chahal, Petersen, COVID-19 and the UK Biobank-Opportunities and challenges for research and collaboration with other large population studies, Front Cardiovasc Med
Kim, Read, Fauci, Therapy for early COVID-19: A critical need, JAMA
Kutti Sridharan, Kotagiri, Chandiramani, Mohan, Vegunta et al., COVID-19 and avoiding Ibuprofen. How good is the evidence?, Am J Ther
Lee, Ha, Yeniova, Moon, Kim et al., Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: A nationwide cohort study with propensity score matching, Gut
Mather, Seip, Mckay, Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19, Am J Gastroenterol
Murai, Fernandes, Sales, Pinto, Goessler et al., Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: A Randomized Clinical Trial, JAMA,
doi:10.1001/jama.2020.26848Pavoni, Gianesello, Pazzi, Stera, Meconi et al., Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action, Thromb Res
Rinott, Kozer, Shapira, Haim, Ibuprofen use and clinical outcomes in COVID-19 patients, Clin Microbiol Infect
Rubin, Sorting out whether vitamin D deficiency raises COVID-19 risk, JAMA
Tan, Ho, Kalimuddin, Cherng, Teh et al., Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B12 in combination on progression to severe outcomes in older patients with coronavirus (COVID-19), Nutrition
Umhau, Casting sunlight on an epidemic: Is vitamin D a critical host factor to prevent COVID-19?, J Infect Dis
Yuan, Wang, Chan, Zhang, Cheng et al., Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virusassociated pneumonia in Syrian hamsters, Nat Microbiol
Zhou, Wang, Lee, Wu, Cheung et al., Proton pump inhibitor or famotidine use and severe COVID-19 disease: A propensity score-matched territory-wide study, Gut
Zhu, Salminen, Thompson, Jahanshad, The UK Biobank Data Parser: A tool with built in and customizable filters for brain studies
DOI record:
{
"DOI": "10.21873/invivo.12134",
"ISSN": [
"0258-851X",
"1791-7549"
],
"URL": "http://dx.doi.org/10.21873/invivo.12134",
"alternative-id": [
"10.21873/invivo.12134"
],
"author": [
{
"affiliation": [],
"family": "LEHRER",
"given": "STEVEN",
"sequence": "first"
},
{
"affiliation": [],
"family": "RHEINSTEIN",
"given": "PETER H.",
"sequence": "additional"
}
],
"container-title": "In Vivo",
"container-title-short": "In Vivo",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2020,
8,
31
]
],
"date-time": "2020-08-31T23:25:21Z",
"timestamp": 1598916321000
},
"deposited": {
"date-parts": [
[
2022,
4,
30
]
],
"date-time": "2022-04-30T12:32:03Z",
"timestamp": 1651321923000
},
"indexed": {
"date-parts": [
[
2024,
5,
11
]
],
"date-time": "2024-05-11T15:12:52Z",
"timestamp": 1715440372631
},
"is-referenced-by-count": 96,
"issue": "5",
"issued": {
"date-parts": [
[
2020
]
]
},
"journal-issue": {
"issue": "5",
"published-online": {
"date-parts": [
[
2020,
8,
31
]
]
},
"published-print": {
"date-parts": [
[
2020
]
]
}
},
"language": "en",
"link": [
{
"URL": "https://syndication.highwire.org/content/doi/10.21873/invivo.12134",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "9336",
"original-title": [],
"page": "3023-3026",
"prefix": "10.21873",
"published": {
"date-parts": [
[
2020
]
]
},
"published-online": {
"date-parts": [
[
2020,
8,
31
]
]
},
"published-print": {
"date-parts": [
[
2020
]
]
},
"publisher": "Anticancer Research USA Inc.",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "http://iv.iiarjournals.org/lookup/doi/10.21873/invivo.12134"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2",
"type": "journal-article",
"volume": "34"
}
